Long-term engraftment and maturation of autologous iPSC-derived cardiomyocytes in two rhesus macaques

Yongshun Lin,Noriko Sato,Sogun Hong,Kenta Nakamura,Elisa A Ferrante,Zu Xi Yu,Marcus Y Chen,Daisy S Nakamura,Xiulan Yang,Randall R Clevenger,Timothy J Hunt,Joni L Taylor,Kenneth R Jeffries,Karen J Keeran,Lauren E Neidig,Atul Mehta,Robin Schwartzbeck,Shiqin Judy Yu,Conor Kelly,Keron Navarengom,Kazuyo Takeda,Stephen S Adler,Peter L Choyke,Jizhong Zou,Charles E Murry,Manfred Boehm,Cynthia E Dunbar

DOI: https://doi.org/10.1016/j.stem.2024.05.005

IF: 23.9

2024-07-05

Cell Stem Cell

Abstract:Cellular therapies with cardiomyocytes produced from induced pluripotent stem cells (iPSC-CMs) offer a potential route to cardiac regeneration as a treatment for chronic ischemic heart disease. Here, we report successful long-term engraftment and in vivo maturation of autologous iPSC-CMs in two rhesus macaques with small, subclinical chronic myocardial infarctions, all without immunosuppression. Longitudinal positron emission tomography imaging using the sodium/iodide symporter (NIS) reporter gene revealed stable grafts for over 6 and 12 months, with no teratoma formation. Histological analyses suggested capability of the transplanted iPSC-CMs to mature and integrate with endogenous myocardium, with no sign of immune cell infiltration or rejection. By contrast, allogeneic iPSC-CMs were rejected within 8 weeks of transplantation. This study provides the longest-term safety and maturation data to date in any large animal model, addresses concerns regarding neoantigen immunoreactivity of autologous iPSC therapies, and suggests that autologous iPSC-CMs would similarly engraft and mature in human hearts.